Skip to main content

Table 1 Baseline demographics and clinical characteristics at diagnosis of metastatic breast cancer

From: Eribulin monotherapy improved survivals in patients with ER-positive HER2-negative metastatic breast cancer in the real world: a single institutional review

 Variables Overall Eribulin Noneribulin P value Fisher’s exact test
(N = 293) (N = 66) (N = 227)
Median age, years (range) 54.0 (25–78) 55.0 (27–77) 54.0 (25–78)  
Diagnosis, n (%)
 Metastatic 214 (73.0) 44 (66.7) 170 (74.9) 0.21
 Locally advanced 79 (27.0) 22 (33.3) 57 (25.1)
Sites of metastases, n (%)        
 Lung 71 (24.2) 16 (24.2) 55 (24.2) 1.00
 Liver 58 (19.8) 20 (30.3) 38 (16.7) 0.02*
 Bone 155 (52.9) 35 (53.0) 120 (52.9) 1.00
 CNS 14 (4.8) 3 (0.5) 11 (4.8) 1.00
 Soft tissue 185 (63.2) 44 (66.7) 141 (62.1) 0.56
Treatment regimens, n (%)
 Anthracycline-based regimen for EBC 79 (27.0) 22 (33.3) 57 (25.1)  
 Anthracycline-based regimen for MBC 135 (46.1) 26 (39.4) 109 (48.0)  
 Taxane-based regimen for EBC 39 (13.3) 18 (27.3) 21 (9.3)  
 Taxane-based regimen for MBC 228 (77.8) 53 (80.3) 175 (77.1)  
 Eribulin as first-/second-line for MBC 31 (47.0) 31 (47.0)  
 Taxane-based regimen prior to eribulin 40 (13.7) 40 (60.6)  
  1. CNS central nervous system, EBC early breast cancer, MBC metastatic breast cancer